| Rus |  |
Eng |  |
The Prize is awarded to researchers, scientists and developers (up to three people) being the authors of scientific-technological discovery or discoveries in the field of nanotechnologies, and to the company being the first to apply the discovery (discoveries) to mass production with the annual turnover of at least $10 million and reached business success through the application of the discovery (discoveries).
The RUSNANOPRIZE International Nanotechnology Prize Committee awarded the winners of the 2013 prize, in the field of nanomaterials and surface modification. This year prize goes to Massachusetts Institute of Technology Institute Professor Robert Langer and Harvard Medical School Professor Omid Farokhzad for the development and industrialization of nanoparticle technologies for medical applications.
Prof. Langer and Prof. Farokhzad have created combined nanoparticles, the surfaces of which are covered with biological ligands, i.e. molecules that recognize specific targets in the body, for example, the surface of cancer cells. The interior of the nanoparticles is composed of biologically inert polymer which binds the active substance, for example docetaxel, which is traditionally used in chemotherapy. These particles may circulate for a long time and be retained in the blood, and so they accumulate only around the tumor cells. Based on this technology, in particular, drugs have been created for the treatment of brain tumors, which are difficult to treat with traditional methods.
The winning research is a junction between biotechnology and material science. Prof. Langer’s research has laid foundation for new developments in the field of biomaterials as well as for applying nanomaterials in medicine and biology. Aside from his research in bio-compatible polymers for drug delivery systems with controlled release and synthetic polymers for tissue engineering, Prof. Langer has pioneered creating many other new types of biomaterials, like shape-memory polymers and materials with controlled surface properties.
RUSNANOPRIZE 2013 award was also given to US-based BIND Therapeutics Inc. for the successful commercial application of Prof. Langer’s and Prof. Farokhzad’s research, developing Accurins™ a new class of highly selective targeted and programmable therapeutics.
RUSNANOPRIZE is established to promote Science and Business Integration, Public Awareness of the Achievements in the Nanotechnology Area, International Cooperation, Acknowledgement of the Role of Scientists and Manufacturers.
International RUSNANOPRIZE 2013 Award Committee is represented by famous scientists and innovation businessman, who are generally acknowledged to have achieved outstanding results in the field of this year Prize - nanomaterials and surface modification. This year prof. Yury Gogotsi, Director of the A. J. Drexel Nanotechnology Institute, distinguished chair and professor, Drexel University (USA), also was invited to International Prize Award Committee
Financial rewards, prize symbols and honorary diploma of the Prize are awarded to inventors, scientists and developers, the authors of the R&D projects or technologies implemented into production. The company that has achieved some significant commercial success due to the implementation of these technologies is awarded with an honorary diploma and a glass ball, which is a RUSNANOPRIZE symbol.
The RUSNANOPRIZE 2013 award ceremony was held on November 1 in Moscow as part of the Open Innovations Forum.
Source: www.rusnanoprize.ru
Here we demonstrate a new developed method for depositing Ti3C2Tx MXenes onto hydrophobic electrospun PCL membranes using oxygen plasma treatment. These novel patches hold tremendous potential for providing mechanical support to damaged heart tissue and enabling electrical signal transmission,thereby mimicking the crucial electroconductivity required for normal cardiac function. After a detailed investigation of scaffold-to-cell interplay, including electrical stimulation, novel technology has the potential for clinical application not only for cardiac regeneration, but also as neural and muscular tissue substitutes.
MX-MAP project participants from MRC Dr. Oleksiy Gogotsi and Veronika Zahorodna performed split secondment visit to project partner organization University of Padova (Italy). MX-MAP project works on development of the key strategies for MXene medical applications. 
CanbioSe Project Meeting and Project Workshop was held at European Institute of Membranes (IEM), University of Montpellier, France on September 26-27, 2023. The workshop was focused on the theme of "Commercializing Biosensors, Intellectual Property, and Knowledge Transfer from Academia to Industry.
Dr. Oleksiy Gogotsi and Veronika Zahorodna visited IEEE NAP 2023 conference held in Bratislava on September 10-15, 2023. The prime focus of the IEEE NAP-2023 was on nanoscale materials with emphasis on interdisciplinary research exploring and exploiting their unique physical and chemical proprieties for practical applications.
Director of MRC and Carbon-Ukraine Dr. Oleksiy Gogotsi visited CEST labs in Wiener Neustadt (Low Energy Ion Scattering, Batteries development) and TU Vienna (ELSA, SFA). He meet with Dr. Pierluigi Bilotto, Dr. Chriatian Pichler and their colleagues, discussing novel materials and r&d activities for new technologies.
MX-MAP Session was held during the YUCOMAT Conference 2023 titled: "Towards MXenes’ biomedical applications by high-dimensional immune MAPping", HORIZON-MSCA-2021-SE-01 project MX-MAP.
CANBIOSE project participants from MRC Dr. Oleksiy Gogotsi and Veronika Zahorodna performed secondment visit to project partner organization European Institute of Membranes in Montpellier (France) on August -September 2023.
MRC researchers Dr. Oleksiy Gogotsi and Veronika Zahorodna were visiting Nanobiomedical Centre, Adam Mickewicz University in Poznan, Poland due to close collaboration with AMU team led by Dr. Igor Iatsunskiy. 
Meeting during the MXene international conference held in Drexel University on Aug. 3, 2022, and discussing the roadmap for launching MX-MAP research project on MXenes for medical applications.